Clearmind Medicine Inc.
NASDAQ Capital MarketTotal Valuation
Clearmind Medicine Inc. carries a market capitalization of 2.98M, placing it among publicly traded companies globally. Its enterprise value stands at -9.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.98M |
| Enterprise Value | -9.31M |
Share Statistics
Clearmind Medicine Inc. currently has 1.50M shares outstanding.
| Shares Outstanding | 1.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.24 |
| P/TBV Ratio | 0.13 |
| P/FCF Ratio | -0.19 |
| P/OCF Ratio | -0.19 |
Financial Position
Clearmind Medicine Inc. maintains a current ratio of 3.79, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.10, indicating conservative leverage, while an interest coverage ratio of -1,101.86 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.79 |
| Quick Ratio | 3.71 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | -1,101.86 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -74.91 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 35,070.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Clearmind Medicine Inc.'s stock has declined approximately -99.22629% over the past 52 weeks. The 50-day moving average sits at 7.04, while the 200-day moving average is 135.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.22629% |
| 50-Day Moving Average | 7.04 |
| 200-Day Moving Average | 135.89 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -7.78M, while operating income came in at -7.83M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -7.83M |
| Pretax Income | -6.60M |
| Net Income | -6.64M |
| EBITDA | -7.78M |
| EBIT | -7.83M |
| Earnings Per Share (EPS) | -14.01 |
Balance Sheet
Clearmind Medicine Inc. holds 10.35M in cash and equivalents against 7,977.00 in total debt, resulting in a net debt position of -9.26M. Total book value stands at 4.21M, with working capital of 8.12M providing operational flexibility.
| Cash & Cash Equivalents | 10.35M |
| Total Debt | 7,977.00 |
| Net Debt | -9.26M |
| Equity (Book Value) | 4.21M |
| Book Value Per Share | 8.89 |
| Working Capital | 8.12M |
Cash Flow
Clearmind Medicine Inc. produced -5.55M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.55M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.55M |
| FCF Per Share | -11.72 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -937.02 |
| FCF Yield | -540.14 |
Stock Splits
Clearmind Medicine Inc.'s most recent stock split took place on May 21, 2026 with a 10:1 split ratio.
| Last Split Date | 5/21/2026 |
| Split Ratio | 10:1 |
Scores
Clearmind Medicine Inc. posts an Altman Z-Score of -5.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.27 |